In addition, agents used for DM treatment, such as renal sodium/glucose cotransporter-2 inhibitors (Canagliflozin) 25, glucagon-like peptide-1 (GLP-1) analog (Liraglutide) 26, and metformin 27, also increase the expression of FGF21. Here, FGF21 is linked to diabetes mellitus.